BioSpace News Archive

Procaps Group, a leading integrated international healthcare and pharmaceutical company, announced its financial results for the third quarter ended September 30, 2021.

Results of a long-term safety study of ARAKODA® (tafenoquine) in healthy volunteers have been published in the peer-reviewed journal Travel Medicine and Infectious Disease, according to 60 Degrees Pharmaceuticals, LLC (60P), a pharmaceutical company focused on developing new medicines for tropical diseases.

Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals 18 years of age and older after completion of primary vaccination with any FDA-authorized or approved COVID-19 vaccine.

Context Therapeutics Inc., a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, announced clinical data on onapristone extended release will be presented at the 2021 San Antonio Breast Cancer Symposium taking place virtually and in San Antonio, Texas, from December 7-10, 2021.

ResMed announced it has elected Desney Tan and John Hernandez, both digital health leaders at world-leading tech companies, to its board of directors, during its annual stockholders’ meeting.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of a territory exclusive distribution agreement in Taiwan.

Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, announced that the first manuscript from the landmark SMART study has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG).

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present an update on the Phase 2 IRENE trial in a poster at the 2021 San Antonio Breast Cancer Symposium (SABCS).

MMS Holdings – a data-focused CRO – announced this week the addition of Kevin Chartier, Ph.D., as Principal Advisor of Biostatistics and Submissions Planning. Chartier will work with the biostatistics team across MMS global operations to support Sponsors with complex studies and submissions.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the pricing of an underwritten public offering of 4.7 million American Depositary Shares for gross proceeds of $15.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by RedHill.